ROME — Revised recommendations for the management of ankylosing spondylitis from two international societies set tumor necrosis factor inhibitors as the cornerstone of treatment for patients who fail to have an adequate response to treatment with nonsteroidal anti-inflammatory drugs.
PREVIEW